Phreesia, Inc.
NYSE:PHRMedical - Healthcare Information Services
+$0.08 today
- Market cap
- $760.99M
- Beta
- 0.88
- P/E (TTM)
- 62.6
- EPS (TTM)
- $0.15
Volume 0.86M
Average 1.97M
PHR Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Phreesia, Inc.NYSE: PHR
Accounts Receivables · Q1 FY2027 · quarter ended Apr 2026
Accounts receivables turns positive
Q1 FY2027 accounts receivables was $15.57M, compared with -$1.49M a year earlier. Trailing-twelve-month accounts receivables was $6.91M. Over 3 fiscal years it compounded at -3.0% a year.
Context
- Accounts receivables amounted to 2.1% of revenue in FY2026, unchanged from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near $15.57M or moves back toward the trailing-twelve-month quarterly average of $1.73M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2026
- (10.15M) USD
- Year-over-year change
- -15.2%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2026 | 2026-01-31 | (10.15M) | -15.2% |
| FY2025 | 2025-01-31 | (8.81M) | +21.4% |
| FY2024 | 2024-01-31 | (11.21M) | -0.7% |
| FY2023 | 2023-01-31 | (11.13M) | -9.0% |
| FY2022 | 2022-01-31 | (10.22M) | — |
Accounts Receivables vs competitors
How PHR compares with its peers on the latest reported figures
- PHR's LTM Apr 2026 accounts receivables of $6.91M is the 8th largest of the 11 companies compared; the peer median is $8.14M.
- Its year-over-year change of +177.6% is the 4th highest of 11, against a peer median of +50.5%.
- Accounts receivables amounts to 1.4% of revenue for PHR, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $70.81M | +361.4% | — | 9.0% | |
| LTM Mar 2026 | $29.5M | -6.9% | — | 4.4% | |
| LTM Mar 2026 | $19.4M | +209.1% | — | 0.8% | |
| LTM Sep 2026 | $12.31M | -2.1% | — | 4.6% | |
| LTM Mar 2026 | $12.07M | +71.3% | +46.5% | 4.3% | |
| LTM Jan 2026 | $8.99M | +37.6% | — | 10.7% | |
| LTM Sep 2026 | $7.29M | -28.1% | -2.4% | 2.8% | |
| LTM Apr 2026 | $6.91M | +177.6% | -3.0% | 1.4% | |
| LTM Mar 2026 | $4.99M | +206.8% | — | 0.4% | |
| LTM Mar 2026 | $4.84M | +63.4% | — | 4.9% | |
| LTM Aug 2026 | $407K | -101.7% | — | 0.0% | |
| Peer median (excluding PHR) | $8.14M | +50.5% | +22.0% | 4.3% | |
Competitors are the stored peer set for PHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Jan 2022 | FY2023 Jan 2023 | FY2024 Jan 2024 | FY2025 Jan 2025 | FY2026 Jan 2026 |
|---|---|---|---|---|---|
| Net Income | (118.16M) | (176.15M) | (136.89M) | (58.53M) | 2.31M |
| Depreciation & Amortization | 21.3M | 25.3M | 29.49M | 27.89M | 31.45M |
| Deferred Income Tax | 143K | 434K | 228K | 214K | (13.27M) |
| Stock-Based Compensation | 36.14M | 58.78M | 71.7M | 66.98M | 67.45M |
| Change in Working Capital | (18.57M) | (3.86M) | (1.64M) | (6.49M) | (14.09M) |
| Accounts Receivables | (10.22M) | (11.13M) | (11.21M) | (8.81M) | (10.15M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.88M | 4.77M | (1.99M) | (3.23M) | 5.26M |
| Other Working Capital | (11.24M) | 2.5M | 11.56M | 5.55M | (9.2M) |
| Other Non-Cash Items | 4.43M | 5.37M | 4.73M | 2.33M | 4.96M |
| Operating Cash Flow | (74.71M) | (90.12M) | (32.38M) | 32.38M | 78.81M |
| Capital Expenditures | (30.81M) | (26.2M) | (25.1M) | (24.09M) | (11.1M) |
| Acquisitions (Net) | (34.42M) | 0 | (14.57M) | 0 | (153.19M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 15.71M |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (12.39M) | (21.47M) | (19.29M) | (15.38M) | (13.3M) |
| Investing Cash Flow | (65.23M) | (26.2M) | (39.67M) | (24.09M) | (161.88M) |
| Debt Repayment | (4.27M) | (5.95M) | (6.78M) | (7.81M) | 83.18M |
| Common Stock Issued | 245.81M | 4.92M | 0 | 3.93M | 3.83M |
| Common Stock Repurchased | (9M) | (19.38M) | (12.18M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.42M | (397K) | 1.84M | (7.61M) | (14.15M) |
| Financing Cash Flow | 234.97M | (20.8M) | (17.12M) | (11.49M) | 72.85M |
| Effect of Forex Changes | 0 | 0 | 0 | (106K) | (176K) |
| Net Change in Cash | 95.03M | (137.13M) | (89.16M) | (3.3M) | (10.39M) |
| Free Cash Flow | (105.52M) | (116.33M) | (57.48M) | 8.29M | 67.71M |
Phreesia, Inc.
NYSE:PHR
Intrinsic Alpha fair value
Locked
Current Price
$12.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.